About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Humanigen image

Humanigen

Rank#7166
Market Cap18.76M
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Historyarrow

Humanigen, Inc. was founded in 2015 as Kite Pharma’s wholly-owned research and development subsidiary to focus on G-MAB? technology. Kite announced that it had acquired a majority stake in the company in March 2018. This marked Kite’s first step in entering the Precision Medicine market, as the company sought to expand its pipeline beyond its cancer treatments. Following the acquisition, Humanigen was spun off as a separate, independent company in April 2018.

Missionarrow
Humanigen strives to make a lasting impact on the lives of patients with life-threatening and serious chronic diseases through the development of Humaneered monoclonal antibodies.
Visionarrow
Humanigen aspires to be a global leader in the research and development of Humaneered monoclonal antibodies for the treatment of life-threatening and serious chronic diseases.
Referencesarrow

https://en.wikipedia.org/wiki/Lenzilumab

https://in.investing.com/equities/kalobios-pharmaceuticals-inc

https://finance.yahoo.com/quote/HGEN/profile?p=HGEN

https://www.crunchbase.com/organization/kalobios-pharmaceuticals

https://companiesmarketcap.com/

https://www.humanigen.com

Share

Leadership team
D
Dr. Cameron Durrant M.D., MBA (Chairman, CEO, Principal Financial & Accounting Officer)
D
Dr. Dale Chappell M.B.A., M.D., MBA (Chief Scientific Officer & Director)
M
Mr. Robert Atwill M.B.A. (Sr. VP and Head of Asia-Pacific Region & Bus. Devel.)
Products / Services
Biopharma, Biotechnology, Health Care, Pharmaceutical
Address
Burlingame, California, United States
Established
2001-01-01
Company Registration
SEC CIK number: 0001293310
Revenue
2M - 5M
Traded as
HGEN
Website
https://www.humanigen.com
Social Media
x
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo